Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Induced pluripotent stem cells as a novel cancer vaccine.

Wang L, Pegram MD, Wu JC.

Expert Opin Biol Ther. 2019 Aug 12:1-7. doi: 10.1080/14712598.2019.1650909. [Epub ahead of print]

PMID:
31364894
2.

Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.

Bakre MM, Ramkumar C, Attuluri AK, Basavaraj C, Prakash C, Buturovic L, Madhav L, Naidu N, R P, Somashekhar SP, Gupta S, Doval DC, Pegram MD.

Cancer Med. 2019 Apr;8(4):1755-1764. doi: 10.1002/cam4.2049. Epub 2019 Mar 7.

3.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

PMID:
30811285
4.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.

Pegram MD, Bondarenko I, Zorzetto MMC, Hingmire S, Iwase H, Krivorotko PV, Lee KS, Li RK, Pikiel J, Aggarwal R, Ewesuedo R, Freyman A, Li R, Vana A, Yin D, Zacharchuk C, Tan-Chiu E.

Br J Cancer. 2019 Jan;120(2):172-182. doi: 10.1038/s41416-018-0340-2. Epub 2018 Dec 20.

PMID:
30568294
5.

Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.

Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:65-77. doi: 10.1200/EDBK_200715. Review.

PMID:
30231328
6.

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.

Norton N, Fox N, McCarl CA, Tenner KS, Ballman K, Erskine CL, Necela BM, Northfelt D, Tan WW, Calfa C, Pegram M, Colon-Otero G, Perez EA, Clynes R, Knutson KL.

Breast Cancer Res. 2018 Jun 14;20(1):52. doi: 10.1186/s13058-018-0989-8.

7.

Electrophoretic cytopathology resolves ERBB2 forms with single-cell resolution.

Kang CC, Ward TM, Bockhorn J, Schiffman C, Huang H, Pegram MD, Herr AE.

NPJ Precis Oncol. 2018 Mar 22;2:10. doi: 10.1038/s41698-018-0052-3. eCollection 2018.

8.

Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).

Abraham J, Coleman R, Elias A, Holmes FA, Kalinsky K, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Vogel C; Breast Cancer Therapy Expert Group (BCTEG).

Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4. Review.

PMID:
29725889
9.

Anti-HER2 scFv-Directed Extracellular Vesicle-Mediated mRNA-Based Gene Delivery Inhibits Growth of HER2-Positive Human Breast Tumor Xenografts by Prodrug Activation.

Wang JH, Forterre AV, Zhao J, Frimannsson DO, Delcayre A, Antes TJ, Efron B, Jeffrey SS, Pegram MD, Matin AC.

Mol Cancer Ther. 2018 May;17(5):1133-1142. doi: 10.1158/1535-7163.MCT-17-0827. Epub 2018 Feb 26.

10.

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG).

Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C.

Breast Cancer Res Treat. 2018 May;169(1):1-7. doi: 10.1007/s10549-018-4662-9. Epub 2018 Jan 19. Review.

11.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

12.

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

Diéras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L.

Lancet Oncol. 2017 Jun;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1. Epub 2017 May 16. Erratum in: Lancet Oncol. 2017 Aug;18(8):e433. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.

13.

Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.

Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.

Oncotarget. 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727.

14.

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

Knutson KL, Clynes R, Shreeder B, Yeramian P, Kemp KP, Ballman K, Tenner KS, Erskine CL, Norton N, Northfelt D, Tan W, Calfa C, Pegram M, Mittendorf EA, Perez EA.

Cancer Res. 2016 Jul 1;76(13):3702-10. doi: 10.1158/0008-5472.CAN-15-3091. Epub 2016 Apr 20.

15.

Neratinib in ERBB2-Positive Brain Metastases.

Pegram MD.

JAMA Oncol. 2016 Dec 1;2(12):1541-1543. doi: 10.1001/jamaoncol.2016.0238. No abstract available.

PMID:
27077740
16.

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.

Krop IE, Modi S, LoRusso PM, Pegram M, Guardino E, Althaus B, Lu D, Strasak A, Elias A.

Breast Cancer Res. 2016 Mar 15;18(1):34. doi: 10.1186/s13058-016-0691-7.

17.

Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.

Baselga J, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino AE, Samant MK, Olsen S, de Haas SL, Pegram MD.

Clin Cancer Res. 2016 Aug 1;22(15):3755-63. doi: 10.1158/1078-0432.CCR-15-2499. Epub 2016 Feb 26. Erratum in: Clin Cancer Res. 2018 Nov 1;24(21):5486.

18.

Classification of large circulating tumor cells isolated with ultra-high throughput microfluidic Vortex technology.

Che J, Yu V, Dhar M, Renier C, Matsumoto M, Heirich K, Garon EB, Goldman J, Rao J, Sledge GW, Pegram MD, Sheth S, Jeffrey SS, Kulkarni RP, Sollier E, Di Carlo D.

Oncotarget. 2016 Mar 15;7(11):12748-60. doi: 10.18632/oncotarget.7220.

19.

Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer.

Liu J, Chen X, Ward T, Pegram M, Shen K.

Tumour Biol. 2016 Jul;37(7):9825-35. doi: 10.1007/s13277-015-4650-1. Epub 2016 Jan 26.

PMID:
26810188
20.

Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.

Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M, Shen K.

Int J Biochem Cell Biol. 2016 Feb;71:12-23. doi: 10.1016/j.biocel.2015.11.014. Epub 2015 Nov 28.

PMID:
26643609
21.

COUNTERPOINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.

Pegram MD.

Oncology (Williston Park). 2015 Nov;29(11):797, 801-2. No abstract available.

22.

Hydrogel Pore-Size Modulation for Enhanced Single-Cell Western Blotting.

Duncombe TA, Kang CC, Maity S, Ward TM, Pegram MD, Murthy N, Herr AE.

Adv Mater. 2016 Jan 13;28(2):327-334. doi: 10.1002/adma.201503939. Epub 2015 Nov 16.

23.

"Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic.

Sledge GW, Pegram MD.

Clin Cancer Res. 2015 Jun 15;21(12):2663-5. doi: 10.1158/1078-0432.CCR-14-3183. Erratum in: Clin Cancer Res. 2015 Sep 1;21(17):4024.

24.

Everything old is neu again: cellular senescence in HER2-positive breast cancer.

Sledge GW, Pegram MD.

J Natl Cancer Inst. 2015 May 13;107(5). pii: djv091. doi: 10.1093/jnci/djv091. Print 2015 May. No abstract available.

PMID:
25972602
25.

Personalization of loco-regional care for primary breast cancer patients (part 2).

Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.

Future Oncol. 2015;11(9):1301-5. doi: 10.2217/fon.15.66.

26.

Personalization of loco-regional care for primary breast cancer patients (part 1).

Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.

Future Oncol. 2015;11(9):1297-300. doi: 10.2217/fon.15.65.

27.

Rapid reduction in breast cancer mortality with inorganic arsenic in drinking water.

Smith AH, Marshall G, Yuan Y, Steinmaus C, Liaw J, Smith MT, Wood L, Heirich M, Fritzemeier RM, Pegram MD, Ferreccio C.

EBioMedicine. 2014 Nov 1;1(1):58-63.

28.

Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.

Norton N, Olson RM, Pegram M, Tenner K, Ballman KV, Clynes R, Knutson KL, Perez EA.

Cancer Immunol Res. 2014 Oct;2(10):962-9. doi: 10.1158/2326-6066.CIR-14-0059. Epub 2014 Jul 2.

29.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.

Kaufman PA, Bloom KJ, Burris H, Gralow JR, Mayer M, Pegram M, Rugo HS, Swain SM, Yardley DA, Chau M, Lalla D, Yoo B, Brammer MG, Vogel CL.

Cancer. 2014 Sep 1;120(17):2657-64. doi: 10.1002/cncr.28710. Epub 2014 Jun 13.

30.

Breast cancer version 3.2014.

Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network Breast Cancer Panel.

J Natl Compr Canc Netw. 2014 Apr;12(4):542-90.

PMID:
24717572
31.

Treating the HER2 pathway in early and advanced breast cancer.

Pegram MD.

Hematol Oncol Clin North Am. 2013 Aug;27(4):751-65, viii. doi: 10.1016/j.hoc.2013.05.007. Review.

PMID:
23915743
32.

Treatment combinations for HER2-positive breast cancer.

Pegram M.

Oncology (Williston Park). 2013 Apr;27(4):258, 260. No abstract available.

PMID:
23781688
33.

The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients.

Hurley J, Reis IM, Rodgers SE, Gomez-Fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD.

Breast Cancer Res Treat. 2013 Apr;138(3):783-94. doi: 10.1007/s10549-013-2497-y. Epub 2013 Mar 31.

PMID:
23542956
34.

Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference.

Toi M, Benson JR, Winer EP, Forbes JF, von Minckwitz G, Golshan M, Robertson JF, Sasano H, Cole BF, Chow LW, Pegram MD, Han W, Huang CS, Ikeda T, Kanao S, Lee ES, Noguchi S, Ohno S, Partridge AH, Rouzier R, Tozaki M, Sugie T, Yamauchi A, Inamoto T.

Breast Cancer Res Treat. 2012 Dec;136(3):919-26. doi: 10.1007/s10549-012-2333-9. Epub 2012 Nov 11.

PMID:
23143284
35.

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.

Jegg AM, Ward TM, Iorns E, Hoe N, Zhou J, Liu X, Singh S, Landgraf R, Pegram MD.

Breast Cancer Res Treat. 2012 Dec;136(3):683-92. doi: 10.1007/s10549-012-2252-9. Epub 2012 Oct 23.

PMID:
23089982
36.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group.

N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442.

37.

Tumor biology trumps anatomy in breast cancer brain metastases.

Pegram MD.

Oncology (Williston Park). 2012 Jul;26(7):666, 668, 670. No abstract available.

38.

Truncated p110 ERBB2 induces mammary epithelial cell migration, invasion and orthotopic xenograft formation, and is associated with loss of phosphorylated STAT5.

Ward TM, Iorns E, Liu X, Hoe N, Kim P, Singh S, Dean S, Jegg AM, Gallas M, Rodriguez C, Lippman M, Landgraf R, Pegram MD.

Oncogene. 2013 May 9;32(19):2463-74. doi: 10.1038/onc.2012.256. Epub 2012 Jul 2.

39.

Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.

Iorns E, Ward TM, Dean S, Jegg A, Thomas D, Murugaesu N, Sims D, Mitsopoulos C, Fenwick K, Kozarewa I, Naceur-Lombarelli C, Zvelebil M, Isacke CM, Lord CJ, Ashworth A, Hnatyszyn HJ, Pegram M, Lippman M.

Breast Cancer Res Treat. 2012 Aug;135(1):79-91. doi: 10.1007/s10549-012-2068-7. Epub 2012 Apr 26.

PMID:
22535017
40.

Trastuzumab treatment in multiple lines: current data and future directions.

Pegram M, Liao J.

Clin Breast Cancer. 2012 Feb;12(1):10-8. doi: 10.1016/j.clbc.2011.07.003. Epub 2011 Dec 9. Review.

PMID:
22154153
41.

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer.

Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S.

Breast Cancer Res Treat. 2012 Feb;132(1):215-23. doi: 10.1007/s10549-011-1889-0. Epub 2011 Dec 3.

42.

Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer.

Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M.

Clin Cancer Res. 2011 Nov 1;17(21):6822-30. doi: 10.1158/1078-0432.CCR-11-1151. Epub 2011 Aug 30.

43.

Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer.

Araki K, Saji S, Gallas M, Pegram M, Sasaki Y.

Breast Cancer. 2012 Apr;19(2):95-103. doi: 10.1007/s12282-011-0296-z. Epub 2011 Aug 24. Review.

PMID:
21863310
44.

Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.

Smith TR, Liu-Mares W, Van Emburgh BO, Levine EA, Allen GO, Hill JW, Reis IM, Kresty LA, Pegram MD, Miller MS, Hu JJ.

Carcinogenesis. 2011 Sep;32(9):1354-60. doi: 10.1093/carcin/bgr117. Epub 2011 Jun 23.

45.

HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis.

Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD.

Breast Cancer Res Treat. 2011 Oct;129(3):659-74. doi: 10.1007/s10549-011-1632-x. Epub 2011 Jun 23.

PMID:
21698410
46.

Triple negative breast cancer: unmet medical needs.

Pal SK, Childs BH, Pegram M.

Breast Cancer Res Treat. 2011 Feb;125(3):627-36. doi: 10.1007/s10549-010-1293-1. Epub 2010 Dec 15. Review.

47.

Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.

Albain KS, Carey L, Gradishar WJ, Gralow JR, Lipton A, Rugo H, Tripathy D, Peck S, Abair T, Pegram M.

Clin Breast Cancer. 2010 Dec 1;10(6):421-39. doi: 10.3816/CBC.2010.n.056. Review.

PMID:
21147685
48.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.

Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackey JR, Fumoleau P, Rolski J, Mrsic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF, Slamon DJ.

J Clin Oncol. 2011 Jan 10;29(2):149-56. doi: 10.1200/JCO.2010.28.6450. Epub 2010 Nov 29.

PMID:
21115860
49.

Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene.

Harbeck N, Pegram MD, Rüschoff J, Möbus V.

Breast Care (Basel). 2010;5(s1):3-7. Epub 2010 Apr 26.

50.

Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.

Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X.

Br J Cancer. 2010 Mar 2;102(5):827-32. doi: 10.1038/sj.bjc.6605560. Epub 2010 Feb 16.

Supplemental Content

Loading ...
Support Center